Share

January 02, 2018; 90 (1) Article

Diet quality is associated with disability and symptom severity in multiple sclerosis

Kathryn C. Fitzgerald, Tuula Tyry, Amber Salter, Stacey S. Cofield, Gary Cutter, Robert Fox, Ruth Ann Marrie
First published December 6, 2017, DOI: https://doi.org/10.1212/WNL.0000000000004768
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
753

Share

Article Information

vol. 90 no. 1 e1-e11
DOI: 
https://doi.org/10.1212/WNL.0000000000004768
PubMed: 
29212827
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • Received June 15, 2017
  • Accepted in final form September 7, 2017
  • First Published December 6, 2017.

Article Versions

Copyright & Usage: 
Copyright © 2017 American Academy of Neurology

Author Disclosures

    1. Kathryn C. Fitzgerald, ScD,
    2. Tuula Tyry, PhD,
    3. Amber Salter, PhD,
    4. Stacey S. Cofield, PhD,
    5. Gary Cutter, PhD,
    6. Robert Fox, MD and
    7. Ruth Ann Marrie, MD, PhD
  1. Kathryn C. Fitzgerald, ScD,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. fellowship grants from the National Multiple Sclerosis Society and from the Foundation of the Consortium of Multiple Sclerosis Centers.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Tuula Tyry, PhD,
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Amber Salter, PhD,
    4. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Stacey S. Cofield, PhD,
    5. Scientific Advisory Boards:

    1. (1) MedImmune (2) Orthotech Biotech (3) Department of Defense

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Oxford University Press, reviewer textbook, 2016

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) American Shoulder and Elbow Society

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Pfizer

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. American College of Rheumatology

    Research Support, Foundations and Societies:

    1. Consortium of MS Centers

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Gary Cutter, PhD,
    6. Scientific Advisory Boards:

    1. Participation of Data and Safety Monitoring Committees: AMO Pharmaceuticals, Apotek, Gilead Pharmaceuticals, Horizon Pharmaceuticals, Modigenetech/Prolor, Merck, Merck/Pfizer, Opko Biologics, Sanofi-Aventis, Reata Pharmaceuticals, Receptos/Celgene, Teva pharmaceuticals, NHLBI (Protocol Review Committee), NICHD (OPRU oversight committee).

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Consortium of MS Centers, speaker honoraria; (2) Teva, Speaker honoraria

    Editorial Boards:

    1. (1) Multiple Sclerosis, Editorial Board, 2010-present (2) JASN, 2013- present, statistical consulting reviewer (3) Alzheimers & Dementia: Translational Research & Clinical Interventions

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. (1) Employed by the University of Alabama at Birmingham; (2) President of Pythagoras, Inc. a private consulting company located in Birmingham AL.

    Consultancies:

    1. Argenx BVBA, Atara Biotherapeutics, Consortium of MS Centers (grant), Genzyme, Genentech, Innate Therapeutics, Jannsen Pharmaceuticals, Klein-Buendel Incorporated, Medimmune, Medday, Nivalis, Novartis, Opexa Therapeutics, Roche, Savara Inc., Somahlution, Teva pharmaceuticals, Transparency Life Sciences, TG Therapeutics

    Speakers' Bureaus:

    1. NONE

    Other activities:

    1. (1) NARCOMS MS Patient Registry funded by CMSC

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. No direct grants, but work on studies funded to the Consortium of MS Centers subcontracted for analysis of NARCOMS Registry.

    Research Support, Government Entities:

    1. ACTIVE U01 NS 042685 (Cutter) 09/23/2005 ? 08/31/2015 NIH/NINDS Thymectomy Plus Prednisone vs. Prednisone Alone in NonThymomatous Myasthenia Gravis This multinational clinical trial aims to assess the utility of thymectomy in treating nonthymomatous Myasthenia Gravis patients comparing surgery plus medications versus medications alone. P30-AI 027767 (Saag, M.) 06/01/2014 ? 05/31/2019 NIH/NIAID UAB Center for Aids Research This CFAR is organized as a partnership between the University of Alabama at Birmingham and the Southern Research Institute. The primary purpose of this partnership is to generate interdisciplinary AIDS research efforts. This Center is responsible for planning, evaluating, managing and documenting a broad array of research activities within two institutions. Particular emphasis is placed upon linking clinical and basic science studies through the use of shared facilities and to translate as quickly as possible fundamental knowledge about AIDS and its related disorders into clinical treatment and prevention programs. U01-HL 119242 (Cutter) 09/01/2014 ? 05/31/2020 NIH/NHLBI Chronic Hypertension and Pregnancy (CHAP): Data Coordinating Center We propose a large pragmatic multi-center randomized trial of pregnant women with mild chronic hypertension to evaluate the benefits and harms of antihypertensive therapy to a goal <140/90 mmHg (as recommended for the general population in the US) compared with ACOG's current policy of expectant management of mild chronic hypertension in pregnancy. The trial will be conducted in 12 experienced research-oriented Ob/Gyn departments (including 25 clinical sites) in the United States. The monitoring plan will include a pre-specified option to increase the planned sample size of 4700 women after interim evaluation by an independent Data Safety and Monitoring Board. R01 HD 064729 (Tita) 04/01/2010 ? 07/31/2015 NIH/NICHD Caesarean Section Optimal Antibiotic Prophylaxis (C/SOAP) Trial A multicenter randomized trial to determine the efficacy and safety of a modified (extended-spectrum) antibiotic prophylaxis strategy at cesarean delivery to reduce surgical site infections. R01 AG 021927 (Marson) 07/01/2010 ? 06/30/2015 NIH/NIA Functional Change in Mild Cognitive Impairment (COINS) This R01 project investigates longitudinal change in higher order functional abilities in patients with MCI, and develops predictor models for clinical progression and conversion from MCI to dementia. No number assigned (Cutter) 01/01/2004 ? 12/31/2015 Consortium of MS Centers (CMSC) North American Research Consortium on Multiple Sclerosis (NARCOMS) The goals of this project are to facilitate a confidential way for patients to supply valuable information to researchers about their course of disease that may lead to more effective treatments and care. W81XWH-12-1-0155 (Korf) 05/15/2012 ? 05/14/2017 U.S. Department of Defense NEUTOFIBOMATOSIS CLINICAL CONSORTIUM AWARD This is a cooperative study group that is focusing on multiple trials in NF. The role of the operations center is both as the data center and the overall coordinating of the study group. U01NS45719 (Lublin) 06/01/2004 ? 11/30/2015 NIH/NINDS CombiRx Statistical and Data Management Center A Phase III, multi-center, double-blind, randomized study comparing the combined use of Interferon Beta-1a and Glatiramer Acetate to either agent alone in patients with relapsing remitting multiple sclerosis. 140305 (Greenberg) 09/01/2013 ? 08/31/2016 Patient Centered Outcomes Research Institute Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate (CAPTURE) U34 AR062891 (K. Saag) 04/15/2013 ? 03/31/2015 NIH/NIAMS Effectiveness of DiscontinuinG BisphosphonatEs Study (EDGE) Planning grant for a Pragmatic Clinical Trial (PCT), ?Effectiveness of DiscontinuinG bisphosphonatEs (EDGE) Study?, a ?real world? effectiveness trial of an initially estimated 4,100 patients randomized to continuation or discontinuation of prior alendronate therapy. P30DK079337 (Agarwal) 09/20/13 ? 07/31/18 NIH/NIDDK UAB/UCSD O?Brien Core Center for Acute Kidney Injury Research In summary, these cores and the outstanding cohort of investigators assembled for this center will provide unique expertise that is critical for innovative and productive research in AKI. With its Extended Research Base that includes both clinical and basic investigators, this O'Brien center will accelerate the translation of new investigative insights towards novel therapies for patients with AKI. RSTFD0000541263 (Cutter) 09/01/13 ? 08/31/17 Children?s Hospital (Boston) Early Biomarkers of Autism Spectrum Disorders in Infants with Tuberous Sclerosis MG Registry (Cutter) 01/01/14-present (annually) MGFA This is new registry (1.5 years old) that is a patient registry of Myasthenia Gravis Patients based solely on patient reported outcomes tracking their disease over time. CBD Trial (Cutter) 04/01/2014 ? 9/30/2015 State of Alabama The data management center for the effectiveness of cannabidiol (CBD) oil for the treatment of seizures and epilepsy.

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Consortium of MS Centers (2) Myasthenia Gravis Foundation of America, grant for MG Registry

    Stock/Stock Options/Board of Directors Compensation:

    1. Pythagoras, Inc. Sub S Corporation - President.

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. Galderma Litigation (acne case) reviewed statistical data

  6. Robert Fox, MD and
    7. Scientific Advisory Boards:

    1. Biogen Idec, Novartis

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Editorial Board, Neurology Editorial Board, Multiple Sclerosis Journal

    Patents:

    1. NONE

    Publishing Royalties:

    1. Multiple Sclerosis and Related Disorders, Demos Medical, 2013

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Actelion, Biogen, Genentech, Novartis, Teva, Mallinckrodt, MedDay

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research grant from Novartis and Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society, RC 1004-A-5, 2010- 2013; RG 4778-A-6, 2013-2018; NIH 1U01NS082329-01A1, 2013- 2018; Consortium of MS Centers

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  7. Ruth Ann Marrie, MD, PhD
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Editorial Board Multiple Sclerosis Journal, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received support as site Principal Investigator for clinical trials from Sanofi- Aventis (2007-2015)

    Research Support, Government Entities:

    1. Received support as principal investigator from the Canadian Institutes of Health Research (2010-2019), and Research Manitoba (2014-2019).

    Research Support, Academic Entities:

    1. Waugh Family Chair in Multiple Sclerosis

    Research Support, Foundations and Societies:

    1. Received support as principal investigator from Multiple Sclerosis Society of Canada (2009-2016) and the National Multiple Sclerosis Society (2013-2017), and as co-principal investigator from Multiple Sclerosis Scientific Foundation (2009-2018). Received support from Consortium of Multiple Sclerosis Centers (2004-2009, 2011-2014, 2016-2017), Rx & D Health Research Foundation (2010-2015), Crohn's and Colitis Canada (2014- 2019)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Department of Neurology (K.C.F.), Johns Hopkins School of Medicine, Baltimore, MD; Dignity Health (T.T.), St. Joseph's Hospital and Medical Center, Phoenix, AZ; Division of Biostatistics (A.S.), Washington University in St. Louis School of Medicine, MO; Department of Biostatistics (S.S.C., G.C.), School of Public Health, University of Alabama at Birmingham; Mellen Center (R.F.), Cleveland Clinic Foundation, OH; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
  1. Correspondence
    Dr. Fitzgerald fitzgerald{at}jhmi.edu
View Full Text

Article usage

Article usage: December 2017 to January 2021

AbstractFullPdfSource
Dec 2017682058135Highwire
Jan 20187397197239Highwire
Feb 201810406062Highwire
Mar 201812784140Highwire
Apr 20185613227Highwire
May 20186422323Highwire
Jun 2018429146Highwire
Jul 20184072515Highwire
Aug 201832157Highwire
Sep 20185681111Highwire
Oct 201840565Highwire
Nov 2018404126Highwire
Dec 2018396149Highwire
Jan 2019345109Highwire
Feb 201940038Highwire
Mar 20193881911Highwire
Apr 201943295Highwire
May 2019419815Highwire
Jun 201934449Highwire
Jul 2019454159Highwire
Aug 201984187Highwire
Sep 201950845Highwire
Oct 2019579812Highwire
Nov 2019452911Highwire
Dec 201933989Highwire
Jan 2020239117Highwire
Feb 202025147Highwire
Mar 2020267153Highwire
Apr 202022075Highwire
May 202028642Highwire
Jun 202023085Highwire
Jul 202039044Highwire
Aug 202027342Highwire
Sep 202098066Highwire
Oct 202031878Highwire
Nov 202023541Highwire
Dec 2020274105Highwire
Jan 202122063Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

More Online

CME Course

Related Articles

Topics Discussed

Alert Me